Features of antihypertensive therapy in the Russian population: data from the ESSE-RF3 study
Aim. To evaluate the usage of antihypertensive drugs (AHDs) and their combinations in participants aged 35 to74 years with arterial hypertension (AH) in the population-based study ESSE-RF3.Material and methods. Representative samples of the population aged 35 to 74 years from 15 regions of Russia (n...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2024-03-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/3010 |
| _version_ | 1797232008849522688 |
|---|---|
| author | Yu. A. Balanova S. A. Shalnova V. A. Kutsenko A. E. Imaeva O. E. Ivlev S. E. Evstifeeva A. V. Kapustina M. B. Kotova S. A. Maksimov G. A. Muromtseva T. V. Repkina T. O. Gonoshilova A. V. Kudryavtsev N. I. Belova L. L. Shagrov M. A. Samotrueva A. L. Yasenyavskaya O. A. Bashkina S. V. Glukhovskaya I. A. Levina E. B. Dorzhieva E. Z. Urbanova N. Yu. Borovkova V. K. Kurashin A. S. Tokareva Yu. I. Ragino G. I. Simonova A. D. Khudyakova V. N. Nikulin O. R. Aslyamov G. V. Khokhlova A. V. Solovieva A. A. Rodionov O. V. Kryachkova Yu. Yu. Shamurova E, V. Mikhailov Yu. O. Tarabrina M. G. Ataev M. O. Radzhabov Z. M. Gasanova M. A. Umetov I. A. Hakuasheva i. V. Elgarova E. I. Yamashkina L. А. Balykova A. A. Usanova A. M. Nikitina N. V. Savvina Iu. E. Spiridonova E. A. Naumova V. S. Yudin A. A. Keskinov S. M. Yudin A. V. Kontsevaya O. M. Drapkina |
| author_facet | Yu. A. Balanova S. A. Shalnova V. A. Kutsenko A. E. Imaeva O. E. Ivlev S. E. Evstifeeva A. V. Kapustina M. B. Kotova S. A. Maksimov G. A. Muromtseva T. V. Repkina T. O. Gonoshilova A. V. Kudryavtsev N. I. Belova L. L. Shagrov M. A. Samotrueva A. L. Yasenyavskaya O. A. Bashkina S. V. Glukhovskaya I. A. Levina E. B. Dorzhieva E. Z. Urbanova N. Yu. Borovkova V. K. Kurashin A. S. Tokareva Yu. I. Ragino G. I. Simonova A. D. Khudyakova V. N. Nikulin O. R. Aslyamov G. V. Khokhlova A. V. Solovieva A. A. Rodionov O. V. Kryachkova Yu. Yu. Shamurova E, V. Mikhailov Yu. O. Tarabrina M. G. Ataev M. O. Radzhabov Z. M. Gasanova M. A. Umetov I. A. Hakuasheva i. V. Elgarova E. I. Yamashkina L. А. Balykova A. A. Usanova A. M. Nikitina N. V. Savvina Iu. E. Spiridonova E. A. Naumova V. S. Yudin A. A. Keskinov S. M. Yudin A. V. Kontsevaya O. M. Drapkina |
| author_sort | Yu. A. Balanova |
| collection | DOAJ |
| description | Aim. To evaluate the usage of antihypertensive drugs (AHDs) and their combinations in participants aged 35 to74 years with arterial hypertension (AH) in the population-based study ESSE-RF3.Material and methods. Representative samples of the population aged 35 to 74 years from 15 regions of Russia (n=28731) with a response rate over 70% were examined in the ESSE-RF3 study. Therapy received by 9944 participants with AH (with systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg, or when the subject was taking AHDs) was analyzed. Information about AHDs intake (brand name of the drug) was recorded by questionnaire and coded according to International Nonproprietary Names by classes. Statistical analysis was performed using the open-source R 4.1 environment. Comparison of discrete indicators between groups was performed using Fisher’s exact test. The significance level for all tested hypotheses was taken as.05. The study was approved by the Ethics Committee of FGBI “NMRC TPM” of the Ministry of Health of the Russian Federation, each participant signed an informed consent.Results. Among the patients receiving therapy for AH, angiotensin-converting enzyme inhibitors (ACEIs) were used by 38.8% of participants, angiotensin receptor blockers (ARBs) — 31.6%, betablockers (BBs) — 29.0%, сalcium channel blockers (CCBs) — 21.5%, diuretics — 18.6%, 1.1% — outdated AHDs; 8.6% — other groups of drugs. Monotherapy was used by 53.1% of patients, 33.1% of participants received two, and 13.9% received three AHDs. Among participants taking two or more AHDs (including single-pill combinations (SPC)), males most often received the combination of BB+ ACEI and females — BB+ARBs. SPC AHDs were used by 10.3% of those receiving therapy (males: 9.8%, females: 10.6%). Among SPCs, the top three combinations were CCBs + ACEIs (28%), diuretics + ACEIs (27.5%), and diuretics + ARBs (24.4%).Conclusion. The population study ESSE-RF3, based on the survey of a representative sample of the Russian population aged 35-74 years, showed that more than a half of participants with AH receiving therapy were used the monotherapy, only every tenth of those treated received SPC. The problem of insufficient patients’ literacy was indicated — about 1% of patients received outdated AGPs. In addition, 8.6% of patients used non-AHDs for the treatment of AH. For improving the control of AH treatment, it is necessary to increase the adherence of patients to the prescribed therapy and more strict adherence of doctors to the published guidelines for AH treatment. |
| first_indexed | 2024-04-24T15:53:27Z |
| format | Article |
| id | doaj.art-3073ab7c7929484faa23293cde29a20f |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-04-24T15:53:27Z |
| publishDate | 2024-03-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-3073ab7c7929484faa23293cde29a20f2024-04-01T07:43:44ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532024-03-0120141210.20996/1819-6446-2024-30102186Features of antihypertensive therapy in the Russian population: data from the ESSE-RF3 studyYu. A. Balanova0S. A. Shalnova1V. A. Kutsenko2A. E. Imaeva3O. E. Ivlev4S. E. Evstifeeva5A. V. Kapustina6M. B. Kotova7S. A. Maksimov8G. A. Muromtseva9T. V. Repkina10T. O. Gonoshilova11A. V. Kudryavtsev12N. I. Belova13L. L. Shagrov14M. A. Samotrueva15A. L. Yasenyavskaya16O. A. Bashkina17S. V. Glukhovskaya18I. A. Levina19E. B. Dorzhieva20E. Z. Urbanova21N. Yu. Borovkova22V. K. Kurashin23A. S. Tokareva24Yu. I. Ragino25G. I. Simonova26A. D. Khudyakova27V. N. Nikulin28O. R. Aslyamov29G. V. Khokhlova30A. V. Solovieva31A. A. Rodionov32O. V. Kryachkova33Yu. Yu. Shamurova34E, V. Mikhailov35Yu. O. Tarabrina36M. G. Ataev37M. O. Radzhabov38Z. M. Gasanova39M. A. Umetov40I. A. Hakuasheva41i. V. Elgarova42E. I. Yamashkina43L. А. Balykova44A. A. Usanova45A. M. Nikitina46N. V. Savvina47Iu. E. Spiridonova48E. A. Naumova49V. S. Yudin50A. A. Keskinov51S. M. Yudin52A. V. Kontsevaya53O. M. Drapkina54National Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineRegional Center for Public Health and Medical PreventionRegional Center for Public Health and Medical PreventionNorthern State Medical UniversityNorthern State Medical UniversityNorthern State Medical UniversityAstrakhan State Medical UniversityAstrakhan State Medical UniversityAstrakhan State Medical UniversitySverdlovsk Regional Medical CollegeSverdlovsk Regional Medical CollegeBoyanov Center for Public Health and Medical PreventionBoyanov Center for Public Health and Medical PreventionPrivolzhsky Research Medical UniversityPrivolzhsky Research Medical UniversityPrivolzhsky Research Medical UniversityInstitute of Cytology and Genetics, Siberian Branch of the Russian Academy of SciencesInstitute of Cytology and Genetics, Siberian Branch of the Russian Academy of SciencesInstitute of Cytology and Genetics, Siberian Branch of the Russian Academy of SciencesOrenburg Regional Center for Public Health and Medical PreventionOrenburg Regional Center for Public Health and Medical PreventionOrenburg Regional Center for Public Health and Medical PreventionTver State Medical UniversityTver State Medical UniversityTver State Medical UniversitySouth Ural State Medical UniversitySouth Ural State Medical UniversitySouth Ural State Medical UniversityDagestan State Medical AcademyDagestan Federal Research Centre of the Russian Academy of SciencesDagestan State Medical AcademyKabardino-Balkarian State UniversityKabardino-Balkarian State UniversityKabardino-Balkarian State UniversityOgarev Mordovia State UniversityOgarev Mordovia State UniversityOgarev Mordovia State UniversityRepublican Center for Public Health and Medical PreventionNorth-Eastern Federal UniversityNorth-Eastern Federal UniversityRepublican Center for Public Health and Medical PreventionCenter for Strategic Planning and Management of Biomedical Health RisksCenter for Strategic Planning and Management of Biomedical Health RisksCenter for Strategic Planning and Management of Biomedical Health RisksNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineAim. To evaluate the usage of antihypertensive drugs (AHDs) and their combinations in participants aged 35 to74 years with arterial hypertension (AH) in the population-based study ESSE-RF3.Material and methods. Representative samples of the population aged 35 to 74 years from 15 regions of Russia (n=28731) with a response rate over 70% were examined in the ESSE-RF3 study. Therapy received by 9944 participants with AH (with systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg, or when the subject was taking AHDs) was analyzed. Information about AHDs intake (brand name of the drug) was recorded by questionnaire and coded according to International Nonproprietary Names by classes. Statistical analysis was performed using the open-source R 4.1 environment. Comparison of discrete indicators between groups was performed using Fisher’s exact test. The significance level for all tested hypotheses was taken as.05. The study was approved by the Ethics Committee of FGBI “NMRC TPM” of the Ministry of Health of the Russian Federation, each participant signed an informed consent.Results. Among the patients receiving therapy for AH, angiotensin-converting enzyme inhibitors (ACEIs) were used by 38.8% of participants, angiotensin receptor blockers (ARBs) — 31.6%, betablockers (BBs) — 29.0%, сalcium channel blockers (CCBs) — 21.5%, diuretics — 18.6%, 1.1% — outdated AHDs; 8.6% — other groups of drugs. Monotherapy was used by 53.1% of patients, 33.1% of participants received two, and 13.9% received three AHDs. Among participants taking two or more AHDs (including single-pill combinations (SPC)), males most often received the combination of BB+ ACEI and females — BB+ARBs. SPC AHDs were used by 10.3% of those receiving therapy (males: 9.8%, females: 10.6%). Among SPCs, the top three combinations were CCBs + ACEIs (28%), diuretics + ACEIs (27.5%), and diuretics + ARBs (24.4%).Conclusion. The population study ESSE-RF3, based on the survey of a representative sample of the Russian population aged 35-74 years, showed that more than a half of participants with AH receiving therapy were used the monotherapy, only every tenth of those treated received SPC. The problem of insufficient patients’ literacy was indicated — about 1% of patients received outdated AGPs. In addition, 8.6% of patients used non-AHDs for the treatment of AH. For improving the control of AH treatment, it is necessary to increase the adherence of patients to the prescribed therapy and more strict adherence of doctors to the published guidelines for AH treatment.https://www.rpcardio.online/jour/article/view/3010hypertensionantihypertensive drugsmonotherapycombination therapysingle-pill combinationesse-rf3 |
| spellingShingle | Yu. A. Balanova S. A. Shalnova V. A. Kutsenko A. E. Imaeva O. E. Ivlev S. E. Evstifeeva A. V. Kapustina M. B. Kotova S. A. Maksimov G. A. Muromtseva T. V. Repkina T. O. Gonoshilova A. V. Kudryavtsev N. I. Belova L. L. Shagrov M. A. Samotrueva A. L. Yasenyavskaya O. A. Bashkina S. V. Glukhovskaya I. A. Levina E. B. Dorzhieva E. Z. Urbanova N. Yu. Borovkova V. K. Kurashin A. S. Tokareva Yu. I. Ragino G. I. Simonova A. D. Khudyakova V. N. Nikulin O. R. Aslyamov G. V. Khokhlova A. V. Solovieva A. A. Rodionov O. V. Kryachkova Yu. Yu. Shamurova E, V. Mikhailov Yu. O. Tarabrina M. G. Ataev M. O. Radzhabov Z. M. Gasanova M. A. Umetov I. A. Hakuasheva i. V. Elgarova E. I. Yamashkina L. А. Balykova A. A. Usanova A. M. Nikitina N. V. Savvina Iu. E. Spiridonova E. A. Naumova V. S. Yudin A. A. Keskinov S. M. Yudin A. V. Kontsevaya O. M. Drapkina Features of antihypertensive therapy in the Russian population: data from the ESSE-RF3 study Рациональная фармакотерапия в кардиологии hypertension antihypertensive drugs monotherapy combination therapy single-pill combination esse-rf3 |
| title | Features of antihypertensive therapy in the Russian population: data from the ESSE-RF3 study |
| title_full | Features of antihypertensive therapy in the Russian population: data from the ESSE-RF3 study |
| title_fullStr | Features of antihypertensive therapy in the Russian population: data from the ESSE-RF3 study |
| title_full_unstemmed | Features of antihypertensive therapy in the Russian population: data from the ESSE-RF3 study |
| title_short | Features of antihypertensive therapy in the Russian population: data from the ESSE-RF3 study |
| title_sort | features of antihypertensive therapy in the russian population data from the esse rf3 study |
| topic | hypertension antihypertensive drugs monotherapy combination therapy single-pill combination esse-rf3 |
| url | https://www.rpcardio.online/jour/article/view/3010 |
| work_keys_str_mv | AT yuabalanova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT sashalnova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT vakutsenko featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT aeimaeva featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT oeivlev featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT seevstifeeva featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT avkapustina featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT mbkotova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT samaksimov featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT gamuromtseva featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT tvrepkina featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT togonoshilova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT avkudryavtsev featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT nibelova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT llshagrov featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT masamotrueva featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT alyasenyavskaya featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT oabashkina featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT svglukhovskaya featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT ialevina featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT ebdorzhieva featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT ezurbanova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT nyuborovkova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT vkkurashin featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT astokareva featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT yuiragino featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT gisimonova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT adkhudyakova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT vnnikulin featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT oraslyamov featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT gvkhokhlova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT avsolovieva featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT aarodionov featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT ovkryachkova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT yuyushamurova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT evmikhailov featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT yuotarabrina featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT mgataev featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT moradzhabov featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT zmgasanova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT maumetov featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT iahakuasheva featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT ivelgarova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT eiyamashkina featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT labalykova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT aausanova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT amnikitina featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT nvsavvina featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT iuespiridonova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT eanaumova featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT vsyudin featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT aakeskinov featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT smyudin featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT avkontsevaya featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study AT omdrapkina featuresofantihypertensivetherapyintherussianpopulationdatafromtheesserf3study |